Aquestive Therapeutics (AQST) said Thursday that its Libervant Buccal Film has received seven years of orphan drug exclusivity from the US Food and Drug Administration to treat seizure clusters in patients with epilepsy ages two to five.
The regulator's decision was based on the assessment that Libervant's buccal route of administration offers a "major contribution" to patient care in comparison to the rectal route of administration regarding the ease of use, the company added.
Libervant Buccal Film obtained the FDA's approval in April.
Shares of the company were up more than 3% in recent Thursday trading.
Price: 3.59, Change: +0.13, Percent Change: +3.64
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.